Quantification of outpatient management and hospitalization of patients with high-risk myelodysplastic syndrome treated with low-dose decitabine View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2005-11-16

AUTHORS

J. A. Pitako, P. S. Haas, J. Van den Bosch, H. Müller-Berndorff, A. Kündgen, U. Germing, P. W. Wijermans, M. Lübbert

ABSTRACT

Intravenous low-dose 5-aza-2′-deoxycytidine (decitabine) in patients with advanced myelodysplastic syndrome (MDS) yields an approximately 50% overall response rate, including 20–25% complete remission. Decitabine-treated MDS patients can be managed as outpatients after completion of a 3-day infusion schedule. In-hospital nights (IHNs), overall survival (OS), and remaining life spent in hospital were evaluated and compared to a matched control group receiving different standard treatments. Between July 1992 and September 2001, 99 high-risk MDS patients, median age 70 years (range 49–86), were treated with low-dose decitabine. Durations of all hospitalizations were recorded. For matched-pair analysis, 44 decitabine-treated patients were matched to 44 MDS patients according to International Prognostic Scoring System classification, period of diagnosis, age, French–American–British classification, and gender. Median number of IHN across all patients was 56 and survival was 481 days, resulting in 84% of remaining life spent at home. In the matched-pair analysis, the median number of IHN was 57 in the decitabine group vs. 50 in the control group. Median survival was 400 vs. 371 days for the decitabine and control groups, respectively. Median number of remaining life spent at home was identical (83% for both groups). Matched patients who received only best supportive care (n=12) had a shorter median survival than the decitabine patients (234 vs. 400 days), and the proportion of remaining life spent at home was slightly greater (82 vs. 77%). Interestingly, matched patients with induction therapy showed comparable IHN, OS, and remaining life spent at home. In conclusion, high-risk MDS patients treated with low-dose decitabine have better survival, and spend comparable time in hospital than patients treated with supportive treatment. More... »

PAGES

25-31

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s00277-005-0007-y

DOI

http://dx.doi.org/10.1007/s00277-005-0007-y

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1013880082

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/16292666


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1117", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Public Health and Health Services", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged, 80 and over", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Ambulatory Care", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antineoplastic Agents", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Azacitidine", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Case-Control Studies", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "DNA Modification Methylases", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Decitabine", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Length of Stay", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Matched-Pair Analysis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Myelodysplastic Syndromes", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Quality of Life", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Retrospective Studies", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Survival Analysis", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Division of Hematology/Oncology, Albert Ludwigs University, Freiburg, Germany", 
          "id": "http://www.grid.ac/institutes/grid.5963.9", 
          "name": [
            "Division of Hematology/Oncology, Albert Ludwigs University, Freiburg, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Pitako", 
        "givenName": "J. A.", 
        "id": "sg:person.01010275475.17", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01010275475.17"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Division of Hematology/Oncology, Albert Ludwigs University, Freiburg, Germany", 
          "id": "http://www.grid.ac/institutes/grid.5963.9", 
          "name": [
            "Division of Hematology/Oncology, Albert Ludwigs University, Freiburg, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Haas", 
        "givenName": "P. S.", 
        "id": "sg:person.01330034222.05", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01330034222.05"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Leyenburg Hospital, The Hague, The Netherlands", 
          "id": "http://www.grid.ac/institutes/grid.413591.b", 
          "name": [
            "Leyenburg Hospital, The Hague, The Netherlands"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Van den Bosch", 
        "givenName": "J.", 
        "id": "sg:person.01204034173.22", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01204034173.22"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Division of Hematology/Oncology, Albert Ludwigs University, Freiburg, Germany", 
          "id": "http://www.grid.ac/institutes/grid.5963.9", 
          "name": [
            "Division of Hematology/Oncology, Albert Ludwigs University, Freiburg, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "M\u00fcller-Berndorff", 
        "givenName": "H.", 
        "id": "sg:person.01066343441.82", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01066343441.82"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Heinrich Heine University, D\u00fcsseldorf, Germany", 
          "id": "http://www.grid.ac/institutes/grid.411327.2", 
          "name": [
            "Heinrich Heine University, D\u00fcsseldorf, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "K\u00fcndgen", 
        "givenName": "A.", 
        "id": "sg:person.01107510155.40", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01107510155.40"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Heinrich Heine University, D\u00fcsseldorf, Germany", 
          "id": "http://www.grid.ac/institutes/grid.411327.2", 
          "name": [
            "Heinrich Heine University, D\u00fcsseldorf, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Germing", 
        "givenName": "U.", 
        "id": "sg:person.01362464041.20", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01362464041.20"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Leyenburg Hospital, The Hague, The Netherlands", 
          "id": "http://www.grid.ac/institutes/grid.413591.b", 
          "name": [
            "Leyenburg Hospital, The Hague, The Netherlands"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Wijermans", 
        "givenName": "P. W.", 
        "id": "sg:person.010061377417.22", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.010061377417.22"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Hugstetter Str. 55, 79106, Freiburg, Germany", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Division of Hematology/Oncology, Albert Ludwigs University, Freiburg, Germany", 
            "Hugstetter Str. 55, 79106, Freiburg, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "L\u00fcbbert", 
        "givenName": "M.", 
        "id": "sg:person.01153663723.53", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01153663723.53"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1038/sj.leu.2403289", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1043374573", 
          "https://doi.org/10.1038/sj.leu.2403289"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/bjc.1995.364", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1032504390", 
          "https://doi.org/10.1038/bjc.1995.364"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1023/a:1026427724108", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1046618914", 
          "https://doi.org/10.1023/a:1026427724108"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2005-11-16", 
    "datePublishedReg": "2005-11-16", 
    "description": "Intravenous low-dose 5-aza-2\u2032-deoxycytidine (decitabine) in patients with advanced myelodysplastic syndrome (MDS) yields an approximately 50% overall response rate, including 20\u201325% complete remission. Decitabine-treated MDS patients can be managed as outpatients after completion of a 3-day infusion schedule. In-hospital nights (IHNs), overall survival (OS), and remaining life spent in hospital were evaluated and compared to a matched control group receiving different standard treatments. Between July 1992 and September 2001, 99 high-risk MDS patients, median age 70 years (range 49\u201386), were treated with low-dose decitabine. Durations of all hospitalizations were recorded. For matched-pair analysis, 44 decitabine-treated patients were matched to 44 MDS patients according to International Prognostic Scoring System classification, period of diagnosis, age, French\u2013American\u2013British classification, and gender. Median number of IHN across all patients was 56 and survival was 481 days, resulting in 84% of remaining life spent at home. In the matched-pair analysis, the median number of IHN was 57 in the decitabine group vs. 50 in the control group. Median survival was 400 vs. 371 days for the decitabine and control groups, respectively. Median number of remaining life spent at home was identical (83% for both groups). Matched patients who received only best supportive care (n=12) had a shorter median survival than the decitabine patients (234 vs. 400 days), and the proportion of remaining life spent at home was slightly greater (82 vs. 77%). Interestingly, matched patients with induction therapy showed comparable IHN, OS, and remaining life spent at home. In conclusion, high-risk MDS patients treated with low-dose decitabine have better survival, and spend comparable time in hospital than patients treated with supportive treatment.", 
    "genre": "article", 
    "id": "sg:pub.10.1007/s00277-005-0007-y", 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1358129", 
        "issn": [
          "0939-5555", 
          "1432-0584"
        ], 
        "name": "Annals of Hematology", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "Suppl 1", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "84"
      }
    ], 
    "keywords": [
      "low-dose decitabine", 
      "high-risk MDS patients", 
      "matched-pair analysis", 
      "overall survival", 
      "MDS patients", 
      "myelodysplastic syndrome", 
      "median number", 
      "control group", 
      "median survival", 
      "International Prognostic Scoring System classification", 
      "median age 70 years", 
      "high-risk myelodysplastic syndrome", 
      "decitabine-treated patients", 
      "best supportive care", 
      "advanced myelodysplastic syndrome", 
      "age 70 years", 
      "period of diagnosis", 
      "shorter median survival", 
      "hospitalization of patients", 
      "overall response rate", 
      "hospital nights", 
      "complete remission", 
      "induction therapy", 
      "supportive care", 
      "outpatient management", 
      "supportive treatment", 
      "infusion schedule", 
      "British (FAB) classification", 
      "standard treatment", 
      "decitabine group", 
      "better survival", 
      "patients", 
      "response rate", 
      "decitabine", 
      "survival", 
      "hospitalization", 
      "syndrome", 
      "hospital", 
      "comparable time", 
      "treatment", 
      "group", 
      "days", 
      "IHN", 
      "remission", 
      "home", 
      "outpatients", 
      "therapy", 
      "life", 
      "diagnosis", 
      "care", 
      "age", 
      "system classification", 
      "duration", 
      "conclusion", 
      "gender", 
      "years", 
      "proportion", 
      "number", 
      "completion", 
      "management", 
      "period", 
      "schedule", 
      "classification", 
      "rate", 
      "night", 
      "analysis", 
      "quantification", 
      "time"
    ], 
    "name": "Quantification of outpatient management and hospitalization of patients with high-risk myelodysplastic syndrome treated with low-dose decitabine", 
    "pagination": "25-31", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1013880082"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s00277-005-0007-y"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "16292666"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s00277-005-0007-y", 
      "https://app.dimensions.ai/details/publication/pub.1013880082"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-12-01T06:24", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20221201/entities/gbq_results/article/article_408.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1007/s00277-005-0007-y"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s00277-005-0007-y'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s00277-005-0007-y'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s00277-005-0007-y'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s00277-005-0007-y'


 

This table displays all metadata directly associated to this object as RDF triples.

272 TRIPLES      21 PREDICATES      114 URIs      103 LITERALS      25 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s00277-005-0007-y schema:about N244912422466446080fb783ded02fc0e
2 N2cf7abfcbaf14eb38965bea40a2d1cc6
3 N2d2a2fb9d976439abc9252414fdd6ca5
4 N4595ec0c13b049609211a3e5381cd468
5 N4fa204fedcb443cc98524532f7db783e
6 N592034d2622440898771d484f32c48cc
7 N5cd70f33084c4fe6bd3b50bbae3d17bc
8 N7b1461db43d64cfe833ca0537d09b331
9 N7e3ee2cda86a4a06a85fc43197319c9e
10 N8ab36acf26114868962fddb9f5820908
11 N8ccaf2e4ebb047979c256736014004b9
12 N8d771f85fb644484982e8944d79c76e2
13 N8f19adeb38e94687afc368abbebff0dc
14 N8f48c0db21ac430581fc23f0d9f1131d
15 Na77c5a087f974560ba8e218c39247f2c
16 Nd845be72315f4864ab5c0b43c95e8387
17 Ndc1b5e1800ff4f539b37ec3b279228de
18 Nf84681b00aff43c29c6290aafe404cd3
19 anzsrc-for:11
20 anzsrc-for:1117
21 schema:author Nf29bfba7e1ec44f2a6e036c61bf9ed63
22 schema:citation sg:pub.10.1023/a:1026427724108
23 sg:pub.10.1038/bjc.1995.364
24 sg:pub.10.1038/sj.leu.2403289
25 schema:datePublished 2005-11-16
26 schema:datePublishedReg 2005-11-16
27 schema:description Intravenous low-dose 5-aza-2′-deoxycytidine (decitabine) in patients with advanced myelodysplastic syndrome (MDS) yields an approximately 50% overall response rate, including 20–25% complete remission. Decitabine-treated MDS patients can be managed as outpatients after completion of a 3-day infusion schedule. In-hospital nights (IHNs), overall survival (OS), and remaining life spent in hospital were evaluated and compared to a matched control group receiving different standard treatments. Between July 1992 and September 2001, 99 high-risk MDS patients, median age 70 years (range 49–86), were treated with low-dose decitabine. Durations of all hospitalizations were recorded. For matched-pair analysis, 44 decitabine-treated patients were matched to 44 MDS patients according to International Prognostic Scoring System classification, period of diagnosis, age, French–American–British classification, and gender. Median number of IHN across all patients was 56 and survival was 481 days, resulting in 84% of remaining life spent at home. In the matched-pair analysis, the median number of IHN was 57 in the decitabine group vs. 50 in the control group. Median survival was 400 vs. 371 days for the decitabine and control groups, respectively. Median number of remaining life spent at home was identical (83% for both groups). Matched patients who received only best supportive care (n=12) had a shorter median survival than the decitabine patients (234 vs. 400 days), and the proportion of remaining life spent at home was slightly greater (82 vs. 77%). Interestingly, matched patients with induction therapy showed comparable IHN, OS, and remaining life spent at home. In conclusion, high-risk MDS patients treated with low-dose decitabine have better survival, and spend comparable time in hospital than patients treated with supportive treatment.
28 schema:genre article
29 schema:isAccessibleForFree false
30 schema:isPartOf N5c7b297115574b498c6aa83a72ec118a
31 N73bdedc2a3964174865545663d7f40be
32 sg:journal.1358129
33 schema:keywords British (FAB) classification
34 IHN
35 International Prognostic Scoring System classification
36 MDS patients
37 advanced myelodysplastic syndrome
38 age
39 age 70 years
40 analysis
41 best supportive care
42 better survival
43 care
44 classification
45 comparable time
46 complete remission
47 completion
48 conclusion
49 control group
50 days
51 decitabine
52 decitabine group
53 decitabine-treated patients
54 diagnosis
55 duration
56 gender
57 group
58 high-risk MDS patients
59 high-risk myelodysplastic syndrome
60 home
61 hospital
62 hospital nights
63 hospitalization
64 hospitalization of patients
65 induction therapy
66 infusion schedule
67 life
68 low-dose decitabine
69 management
70 matched-pair analysis
71 median age 70 years
72 median number
73 median survival
74 myelodysplastic syndrome
75 night
76 number
77 outpatient management
78 outpatients
79 overall response rate
80 overall survival
81 patients
82 period
83 period of diagnosis
84 proportion
85 quantification
86 rate
87 remission
88 response rate
89 schedule
90 shorter median survival
91 standard treatment
92 supportive care
93 supportive treatment
94 survival
95 syndrome
96 system classification
97 therapy
98 time
99 treatment
100 years
101 schema:name Quantification of outpatient management and hospitalization of patients with high-risk myelodysplastic syndrome treated with low-dose decitabine
102 schema:pagination 25-31
103 schema:productId N1a02e030c44d4b229c8ce574c7803f2a
104 N75bbf955c6ae45fa90f8385b74a27733
105 Nc28a165a105644df8b6df0f4229f46de
106 schema:sameAs https://app.dimensions.ai/details/publication/pub.1013880082
107 https://doi.org/10.1007/s00277-005-0007-y
108 schema:sdDatePublished 2022-12-01T06:24
109 schema:sdLicense https://scigraph.springernature.com/explorer/license/
110 schema:sdPublisher N9c317e7725f04f47ad1bc8288abf97a1
111 schema:url https://doi.org/10.1007/s00277-005-0007-y
112 sgo:license sg:explorer/license/
113 sgo:sdDataset articles
114 rdf:type schema:ScholarlyArticle
115 N0dfe0caff5984330abf437d9dfff7aaa rdf:first sg:person.01330034222.05
116 rdf:rest N9ac01fb91ca6407484c48b8c8c7534a3
117 N1a02e030c44d4b229c8ce574c7803f2a schema:name dimensions_id
118 schema:value pub.1013880082
119 rdf:type schema:PropertyValue
120 N244912422466446080fb783ded02fc0e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
121 schema:name Female
122 rdf:type schema:DefinedTerm
123 N2cf7abfcbaf14eb38965bea40a2d1cc6 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
124 schema:name Middle Aged
125 rdf:type schema:DefinedTerm
126 N2d2a2fb9d976439abc9252414fdd6ca5 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
127 schema:name Myelodysplastic Syndromes
128 rdf:type schema:DefinedTerm
129 N4595ec0c13b049609211a3e5381cd468 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
130 schema:name DNA Modification Methylases
131 rdf:type schema:DefinedTerm
132 N4fa204fedcb443cc98524532f7db783e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
133 schema:name Aged, 80 and over
134 rdf:type schema:DefinedTerm
135 N592034d2622440898771d484f32c48cc schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
136 schema:name Quality of Life
137 rdf:type schema:DefinedTerm
138 N5c7b297115574b498c6aa83a72ec118a schema:volumeNumber 84
139 rdf:type schema:PublicationVolume
140 N5cd70f33084c4fe6bd3b50bbae3d17bc schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
141 schema:name Male
142 rdf:type schema:DefinedTerm
143 N73bdedc2a3964174865545663d7f40be schema:issueNumber Suppl 1
144 rdf:type schema:PublicationIssue
145 N75bbf955c6ae45fa90f8385b74a27733 schema:name doi
146 schema:value 10.1007/s00277-005-0007-y
147 rdf:type schema:PropertyValue
148 N77235f5b046f462d8e68aeb7d381f7f4 rdf:first sg:person.010061377417.22
149 rdf:rest N91c793387b8947839cb979d334824041
150 N7b1461db43d64cfe833ca0537d09b331 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
151 schema:name Survival Analysis
152 rdf:type schema:DefinedTerm
153 N7e3ee2cda86a4a06a85fc43197319c9e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
154 schema:name Aged
155 rdf:type schema:DefinedTerm
156 N844e783e0d82498b9452ba88d5783f14 rdf:first sg:person.01107510155.40
157 rdf:rest Nd7bacc32f8a74a76828b66f2e78c3188
158 N8ab36acf26114868962fddb9f5820908 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
159 schema:name Decitabine
160 rdf:type schema:DefinedTerm
161 N8ccaf2e4ebb047979c256736014004b9 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
162 schema:name Length of Stay
163 rdf:type schema:DefinedTerm
164 N8d771f85fb644484982e8944d79c76e2 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
165 schema:name Retrospective Studies
166 rdf:type schema:DefinedTerm
167 N8f19adeb38e94687afc368abbebff0dc schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
168 schema:name Case-Control Studies
169 rdf:type schema:DefinedTerm
170 N8f48c0db21ac430581fc23f0d9f1131d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
171 schema:name Azacitidine
172 rdf:type schema:DefinedTerm
173 N91c793387b8947839cb979d334824041 rdf:first sg:person.01153663723.53
174 rdf:rest rdf:nil
175 N9ac01fb91ca6407484c48b8c8c7534a3 rdf:first sg:person.01204034173.22
176 rdf:rest Ncf8453b78a5445839965f5a3ff2a4680
177 N9c317e7725f04f47ad1bc8288abf97a1 schema:name Springer Nature - SN SciGraph project
178 rdf:type schema:Organization
179 Na77c5a087f974560ba8e218c39247f2c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
180 schema:name Matched-Pair Analysis
181 rdf:type schema:DefinedTerm
182 Nc28a165a105644df8b6df0f4229f46de schema:name pubmed_id
183 schema:value 16292666
184 rdf:type schema:PropertyValue
185 Ncf8453b78a5445839965f5a3ff2a4680 rdf:first sg:person.01066343441.82
186 rdf:rest N844e783e0d82498b9452ba88d5783f14
187 Nd7bacc32f8a74a76828b66f2e78c3188 rdf:first sg:person.01362464041.20
188 rdf:rest N77235f5b046f462d8e68aeb7d381f7f4
189 Nd845be72315f4864ab5c0b43c95e8387 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
190 schema:name Humans
191 rdf:type schema:DefinedTerm
192 Ndc1b5e1800ff4f539b37ec3b279228de schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
193 schema:name Ambulatory Care
194 rdf:type schema:DefinedTerm
195 Nf29bfba7e1ec44f2a6e036c61bf9ed63 rdf:first sg:person.01010275475.17
196 rdf:rest N0dfe0caff5984330abf437d9dfff7aaa
197 Nf84681b00aff43c29c6290aafe404cd3 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
198 schema:name Antineoplastic Agents
199 rdf:type schema:DefinedTerm
200 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
201 schema:name Medical and Health Sciences
202 rdf:type schema:DefinedTerm
203 anzsrc-for:1117 schema:inDefinedTermSet anzsrc-for:
204 schema:name Public Health and Health Services
205 rdf:type schema:DefinedTerm
206 sg:journal.1358129 schema:issn 0939-5555
207 1432-0584
208 schema:name Annals of Hematology
209 schema:publisher Springer Nature
210 rdf:type schema:Periodical
211 sg:person.010061377417.22 schema:affiliation grid-institutes:grid.413591.b
212 schema:familyName Wijermans
213 schema:givenName P. W.
214 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.010061377417.22
215 rdf:type schema:Person
216 sg:person.01010275475.17 schema:affiliation grid-institutes:grid.5963.9
217 schema:familyName Pitako
218 schema:givenName J. A.
219 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01010275475.17
220 rdf:type schema:Person
221 sg:person.01066343441.82 schema:affiliation grid-institutes:grid.5963.9
222 schema:familyName Müller-Berndorff
223 schema:givenName H.
224 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01066343441.82
225 rdf:type schema:Person
226 sg:person.01107510155.40 schema:affiliation grid-institutes:grid.411327.2
227 schema:familyName Kündgen
228 schema:givenName A.
229 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01107510155.40
230 rdf:type schema:Person
231 sg:person.01153663723.53 schema:affiliation grid-institutes:None
232 schema:familyName Lübbert
233 schema:givenName M.
234 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01153663723.53
235 rdf:type schema:Person
236 sg:person.01204034173.22 schema:affiliation grid-institutes:grid.413591.b
237 schema:familyName Van den Bosch
238 schema:givenName J.
239 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01204034173.22
240 rdf:type schema:Person
241 sg:person.01330034222.05 schema:affiliation grid-institutes:grid.5963.9
242 schema:familyName Haas
243 schema:givenName P. S.
244 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01330034222.05
245 rdf:type schema:Person
246 sg:person.01362464041.20 schema:affiliation grid-institutes:grid.411327.2
247 schema:familyName Germing
248 schema:givenName U.
249 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01362464041.20
250 rdf:type schema:Person
251 sg:pub.10.1023/a:1026427724108 schema:sameAs https://app.dimensions.ai/details/publication/pub.1046618914
252 https://doi.org/10.1023/a:1026427724108
253 rdf:type schema:CreativeWork
254 sg:pub.10.1038/bjc.1995.364 schema:sameAs https://app.dimensions.ai/details/publication/pub.1032504390
255 https://doi.org/10.1038/bjc.1995.364
256 rdf:type schema:CreativeWork
257 sg:pub.10.1038/sj.leu.2403289 schema:sameAs https://app.dimensions.ai/details/publication/pub.1043374573
258 https://doi.org/10.1038/sj.leu.2403289
259 rdf:type schema:CreativeWork
260 grid-institutes:None schema:alternateName Hugstetter Str. 55, 79106, Freiburg, Germany
261 schema:name Division of Hematology/Oncology, Albert Ludwigs University, Freiburg, Germany
262 Hugstetter Str. 55, 79106, Freiburg, Germany
263 rdf:type schema:Organization
264 grid-institutes:grid.411327.2 schema:alternateName Heinrich Heine University, Düsseldorf, Germany
265 schema:name Heinrich Heine University, Düsseldorf, Germany
266 rdf:type schema:Organization
267 grid-institutes:grid.413591.b schema:alternateName Leyenburg Hospital, The Hague, The Netherlands
268 schema:name Leyenburg Hospital, The Hague, The Netherlands
269 rdf:type schema:Organization
270 grid-institutes:grid.5963.9 schema:alternateName Division of Hematology/Oncology, Albert Ludwigs University, Freiburg, Germany
271 schema:name Division of Hematology/Oncology, Albert Ludwigs University, Freiburg, Germany
272 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...